ArrePath
Deciphering biology, discovering new classes of anti-infectives
Princeton, United States · Founded 2021 · $21.3M raised
- Headquarters
- Princeton, New Jersey
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- arrepath.com
- Total Funding
- $21.3M
- Last Round
- $1.3M Series AJun 2025
- Rounds
- 3
About
ArrePath is a Princeton-based biotech company applying AI, machine learning, and advanced imaging technologies to discover new classes of small molecule anti-infectives targeting antimicrobial resistance. The company was spun out of Princeton University's Gitai Lab and has developed early proof-of-concept antibiotics now advancing toward clinical development.
Summary
ArrePath is a Life Sciences company based in Princeton, United States, founded in 2021. It has raised $21.3M in total across 3 rounds, most recently a $1.3M Series A round in Jun 2025. Investors include Boehringer Ingelheim Venture Fund, Pace Ventures and Insight Partners.
Tech & App Stack
6 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
PHC is a leading provider of diabetes monitoring systems, specialized laboratory equipment, and c...
BridgeBio makes targeted treatments for genetic diseases.